Anybody hear using Pyri from Minoxidilmax and seeing results/stop of shedding from it? 11/15/2022
Users discussed using pyrilutamide from Minoxidilmax for hair loss, with some reporting reduced shedding and anti-androgenic side effects like reduced sex drive. Dosages varied, with some using 2.5mg or 5mg daily, and costs were noted as a concern.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Is there a consensus on RU these days? Pyril turned out to be a bust right?
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
community DIY Testosterone replacement therapy and fin
An 18-year-old is considering testosterone replacement therapy with finasteride or dutasteride for hair loss but worries about side effects. Users recommend alternatives like minoxidil, RU58841, and consulting a doctor.
community What I’ve learned From 8 Months on Pyrilutamide
Pyrilutamide helps maintain hair density but is less effective than finasteride and needs consistent use. It works best with minoxidil, alfatrodial, and nizoral, though it is costly and inconvenient.
community What is the ultimate hair regrowth protocol
The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.
community 16month progress on crazy stack
The user has been using a strong combination of hair loss treatments for 16 months, including Finasteride, Minoxidil, Dutasteride, and RU-58841, but their hair loss has worsened. They're questioning whether their high testosterone levels or residual scalp DHT are causing further hair loss, with a reply suggesting that even small amounts of DHT can cause hair loss if one is sensitive to it.
Related Research
6 / 6 resultsresearch 587 Efficacy and Safety of topical KX-826 in Male Subjects with Androgenetic Alopecia:A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study
Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
research The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.